HRP20171256T1 - Farmaceutski pripravci karbetocina - Google Patents

Farmaceutski pripravci karbetocina Download PDF

Info

Publication number
HRP20171256T1
HRP20171256T1 HRP20171256TT HRP20171256T HRP20171256T1 HR P20171256 T1 HRP20171256 T1 HR P20171256T1 HR P20171256T T HRP20171256T T HR P20171256TT HR P20171256 T HRP20171256 T HR P20171256T HR P20171256 T1 HRP20171256 T1 HR P20171256T1
Authority
HR
Croatia
Prior art keywords
preparation
carbetocin
preparation according
buffer
methionine
Prior art date
Application number
HRP20171256TT
Other languages
English (en)
Croatian (hr)
Inventor
Anders Nilsson
Mattias Malm
Kazimierz Wisniewski
Britta Siekmann
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171256(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of HRP20171256T1 publication Critical patent/HRP20171256T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
HRP20171256TT 2010-09-30 2011-09-29 Farmaceutski pripravci karbetocina HRP20171256T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition
EP11776530.5A EP2621468B1 (en) 2010-09-30 2011-09-29 Pharmaceutical composition of carbetocin

Publications (1)

Publication Number Publication Date
HRP20171256T1 true HRP20171256T1 (hr) 2017-10-20

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20171256TT HRP20171256T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravci karbetocina
HRP20250382TT HRP20250382T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak koji sadrži karbetocin
HRP20211969TT HRP20211969T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak karbetocina

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20250382TT HRP20250382T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak koji sadrži karbetocin
HRP20211969TT HRP20211969T1 (hr) 2010-09-30 2011-09-29 Farmaceutski pripravak karbetocina

Country Status (27)

Country Link
US (4) US9566311B2 (https=)
EP (5) EP2621468B1 (https=)
JP (2) JP6038797B2 (https=)
KR (2) KR101919119B1 (https=)
CN (4) CN104906032A (https=)
AU (1) AU2011309762B2 (https=)
BR (2) BR122021001123B1 (https=)
CA (1) CA2812510A1 (https=)
CY (2) CY1119245T1 (https=)
DK (4) DK2621468T3 (https=)
ES (4) ES2905561T3 (https=)
FI (1) FI4374878T3 (https=)
HR (3) HRP20171256T1 (https=)
HU (4) HUE034367T2 (https=)
IL (3) IL225238B (https=)
JO (3) JO3400B1 (https=)
LT (3) LT4374878T (https=)
MX (3) MX395271B (https=)
NZ (1) NZ609719A (https=)
PL (4) PL4374878T3 (https=)
PT (4) PT3222272T (https=)
RS (3) RS66759B1 (https=)
RU (2) RU2737264C2 (https=)
SI (4) SI3222272T1 (https=)
SM (3) SMT202500165T1 (https=)
TW (6) TWI750934B (https=)
WO (1) WO2012042371A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
JP2015516415A (ja) * 2012-05-08 2015-06-11 ディラフォール・アクチボラゲットＤｉｌａｆｏｒ Ａｂ 化学修飾ヘパリンまたはヘパラン硫酸および子宮収縮剤を用いた分娩後出血の処置
ES2970059T3 (es) * 2014-09-19 2024-05-24 Ferring Bv Método de tratamiento del síndrome de Prader-Willi
RU2701199C2 (ru) 2014-10-01 2019-09-25 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
PL3200764T3 (pl) 2014-10-01 2020-12-28 Oxytone Bioscience B.V. Rozpadająca się w jamie ustnej stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
HUE070412T2 (hu) 2016-04-12 2025-06-28 Tonix Pharma Ltd Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
BR112020001832A2 (pt) * 2017-08-11 2020-07-28 Ferring B.V. método de produção de uma composição farmacêuti-ca
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
EP3759121A1 (en) 2018-03-01 2021-01-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
TW202031283A (zh) * 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
JP2023500763A (ja) * 2019-11-04 2023-01-11 フェリング ベスローテン フェンノートシャップ 泌乳の改善のためのメロトシンの鼻腔内投与
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
ES3010259T3 (en) 2021-03-26 2025-04-01 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
WO2024211393A2 (en) 2023-04-04 2024-10-10 Tulex Pharmaceuticals Inc. Desmopressin oral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DE69719189T2 (de) 1997-11-18 2003-11-27 Uni-Pharma Kleon Tsetis A.B.E.E., Farmakeftika Ergastiria Pharmazeutische injizierbare Lösungen, die Paracetamol und Kombinationen aus Paracetamol mit anderen Aktivsubstanzen enthalten
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
EP1556068B1 (en) 2002-10-03 2010-08-18 Neuropharmacology Services, LLC Oxytocin for use in the treatment of Autism and Asperger's disorder
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US20100143485A1 (en) 2003-03-05 2010-06-10 Hudnut Paul S Oxycontin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2689476C (en) * 2007-06-07 2014-08-05 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
ES2355196T3 (es) 2007-07-02 2011-03-23 Sime Darby Malaysia Berhad Composición de grasa para la fritura.
ES2319054B1 (es) * 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
EP2260053B1 (en) * 2008-03-31 2014-05-14 Ferring BV Oxytocin analogues
JP5643762B2 (ja) * 2008-10-15 2014-12-17 インターシア セラピューティクス，インコーポレイティド 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用

Also Published As

Publication number Publication date
DK3246018T3 (da) 2022-01-17
MX395271B (es) 2025-03-21
PL4374878T3 (pl) 2025-06-09
JOP20180102A1 (ar) 2019-01-30
US20170106044A1 (en) 2017-04-20
BR122021001123B1 (pt) 2021-05-18
IL225238A0 (en) 2013-06-27
ES2902418T3 (es) 2022-03-28
DK3222272T3 (da) 2022-01-24
RU2737264C2 (ru) 2020-11-26
KR101919119B1 (ko) 2018-11-15
EP3222272B1 (en) 2021-11-03
KR20180123599A (ko) 2018-11-16
TWI680773B (zh) 2020-01-01
JOP20180103A1 (ar) 2019-01-30
KR102102664B1 (ko) 2020-04-22
RU2016143751A (ru) 2018-12-18
RS66759B1 (sr) 2025-05-30
HUE056835T2 (hu) 2022-03-28
TWI650134B (zh) 2019-02-11
IL245328A0 (en) 2016-06-30
ES3027637T3 (en) 2025-06-16
IL245328B (en) 2022-04-01
EP3222272A1 (en) 2017-09-27
SI2621468T1 (sl) 2017-10-30
MX352949B (es) 2017-12-15
MX390779B (es) 2025-03-21
DK2621468T3 (en) 2017-09-11
US20230124105A1 (en) 2023-04-20
TWI750934B (zh) 2021-12-21
TWI746951B (zh) 2021-11-21
PT3246018T (pt) 2022-01-13
PL2621468T3 (pl) 2017-11-30
SI4374878T1 (sl) 2025-06-30
US20130210746A1 (en) 2013-08-15
EP2621468B1 (en) 2017-06-14
JP2017048226A (ja) 2017-03-09
CN103124554A (zh) 2013-05-29
TW201940188A (zh) 2019-10-16
WO2012042371A3 (en) 2013-04-04
HUE034367T2 (en) 2018-02-28
CN107412728A (zh) 2017-12-01
HUE070972T2 (hu) 2025-07-28
CY1119245T1 (el) 2018-02-14
US20170106043A1 (en) 2017-04-20
LT3222272T (lt) 2021-12-27
JOP20180102B1 (ar) 2022-03-15
JP6250770B2 (ja) 2017-12-20
DK4374878T3 (da) 2025-05-05
RU2013112666A (ru) 2014-11-10
SMT202200034T1 (it) 2022-03-21
SI3246018T1 (sl) 2022-02-28
TW202112389A (zh) 2021-04-01
HRP20250382T1 (hr) 2025-05-23
EP4374878B1 (en) 2025-02-12
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
CN107080832B (zh) 2021-05-07
EP4374878A2 (en) 2024-05-29
TWI532507B (zh) 2016-05-11
EP2621468A2 (en) 2013-08-07
CY1124924T1 (el) 2023-01-05
SMT202500165T1 (it) 2025-05-12
RU2016143751A3 (https=) 2020-01-16
JOP20180103B1 (ar) 2022-03-15
HUE057187T2 (hu) 2022-04-28
ES2905561T3 (es) 2022-04-11
IL245326B (en) 2021-04-29
HRP20211969T1 (hr) 2022-03-18
CA2812510A1 (en) 2012-04-05
RS62873B1 (sr) 2022-02-28
BR112013007362B1 (pt) 2021-05-25
JP2013543492A (ja) 2013-12-05
CN104906032A (zh) 2015-09-16
RU2604690C2 (ru) 2016-12-10
TW201729797A (zh) 2017-09-01
JO3400B1 (ar) 2019-10-20
HK1246170A1 (en) 2018-09-07
KR20130136467A (ko) 2013-12-12
MX2013003365A (es) 2013-07-29
SI3222272T1 (sl) 2022-01-31
TW201605466A (zh) 2016-02-16
EP3246018B1 (en) 2021-11-03
WO2012042371A2 (en) 2012-04-05
PL3222272T3 (pl) 2022-03-07
ES2637988T3 (es) 2017-10-18
NZ609719A (en) 2014-07-25
JP6038797B2 (ja) 2016-12-07
US9566311B2 (en) 2017-02-14
LT2621468T (lt) 2017-11-27
IL225238B (en) 2018-07-31
SMT201700420T1 (it) 2017-11-15
AU2011309762B2 (en) 2014-07-17
BR112013007362A2 (pt) 2016-07-12
TW201605465A (zh) 2016-02-16
CN107080832A (zh) 2017-08-22
IL245326A0 (en) 2016-06-30
EP3246018A1 (en) 2017-11-22
AU2011309762A1 (en) 2013-04-04
PT4374878T (pt) 2025-05-02
PT2621468T (pt) 2017-09-08
PL3246018T3 (pl) 2022-05-02
RS56220B1 (sr) 2017-11-30
TWI661834B (zh) 2019-06-11
LT4374878T (lt) 2025-04-25
EP4374878A3 (en) 2024-07-24
FI4374878T3 (fi) 2025-05-16
EP3936117A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
BR112014030820A2 (pt) formulação de anticorpos
HRP20191477T1 (hr) Farmaceutski sastav s-ketamin hidroklorida
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
EP4233892A3 (en) Stable anti-ifnar1 formulation
EA201492021A1 (ru) Антительный состав
AR073567A1 (es) Formulaciones de peptidos y sus usos. metodo
BR112013017750A8 (pt) nanocápsulas com revestimento polimérico
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
JP2011026348A5 (https=)
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
HRP20130123T1 (hr) Postupak lijeäśenja bolesti
HRP20171678T1 (hr) Postupci za smanjenje prejedanja ili kompulzivnog jedenja
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
HRP20190677T4 (hr) Optimizirana farmaceutska formula za liječenje upalnih promjena u jednjaku
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
BR112014009242A8 (pt) nanossuspensão farmacêutica
HRP20211696T1 (hr) Postupak izrade fluoriranih olefina
HRP20230762T1 (hr) Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
HRP20201161T1 (hr) Formulacije sa smanjenom oksidacijom
GT201500001A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
RU2012129115A (ru) Способ лечения острых послеродовых эндометритов у коров
EP4367086A2 (en) Compositions and methods for treating and preventing viral infections
ME02103B (me) Formulacije za goveđi čimbenik stimulacije kolonija granulocita i njegove varijante